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Abstract
Background—QT-interval (QT) prolongation is an established risk factor for ventricular 
tachyarrhythmia and sudden cardiac death. Previous genome-wide association studies in 
populations of the European descent have identified multiple genetic loci that influence QT, but 
few have examined these loci in ethnically diverse populations.
Corresponding Author: Amanda A. Seyerle, Department of Epidemiology, University of North Carolina Chapel Hill, CVS Plaza, 137 
E. Franklin St., Suite 306, Chapel Hill, NC 27514, (919) 966-9304 (voice), (919) 966-9800 (fax), aseyerle@email.unc.edu. 
Conflicts of Interest: None
SDC Supplemental digital content is available through direct URL citations in the HTML and PDF versions of this article 
(www.epidem.com). This content is not peer-reviewed or copy-edited; it is the sole responsibility of the author.
HHS Public Access
Author manuscript
Epidemiology. Author manuscript; available in PMC 2015 March 31.
Published in final edited form as:













Methods—Here, we examine the direction, magnitude, and precision of effect sizes for 21 
previously reported SNPs from 12 QT loci, in populations of European (n=16,398), African 
(n=5,437), American Indian (n=5,032), Hispanic (n=1,143), and Asian (n=932) descent as part of 
the Population Architecture using Genomics and Epidemiology (PAGE) study. Estimates obtained 
from linear regression models stratified by race/ethnicity were combined using inverse-variance 
weighted meta-analysis. Heterogeneity was evaluated using Cochran's Q test.
Results—Of 21 SNPs, seven showed consistent direction of effect across all five populations, 
and an additional nine had estimated effects that were consistent across four populations. Despite 
consistent direction of effect, nine of 16 SNPs had evidence (P < 0.05) of heterogeneity by race/
ethnicity. For these 9 SNPs, linkage disequilibrium plots often indicated substantial variation in 
linkage disequilibrium patterns among the various racial/ethnic groups, as well as possible allelic 
heterogeneity.
Conclusions—These results emphasize the importance of analyzing racial/ethnic groups 
separately in genetic studies. Furthermore, they underscore the possible utility of trans-ethnic 
studies to pinpoint underlying casual variants influencing heritable traits such as QT.
Studies of the QT interval (QT), a measurement of ventricular depolarization and 
repolarization obtained from the electrocardiogram (ECG), have shown that QT 
prolongation is an established risk factor for ventricular tachyarrhythmias,1 coronary heart 
disease,2 sudden cardiovascular death, and all-cause mortality.2 Several correlates of QT 
prolongation have been identified, including structural heart disease,3 sex,4 and age.5 QT is 
also heritable, with estimates ranging from 35%-40%.6
Early family-based linkage studies have identified rare and highly penetrant mutations 
associated with long- and short-QT syndromes.7 Recent genome-wide association studies 
(GWAS) in large population-based studies of European descent populations also have 
identified several common single nucleotide polymorphisms (SNPs) associated with modest 
increases in QT, including NOS1AP, KCNQ1, and SCN5A,8-10 which altogether account for 
approximately 10% of the variance in QT.11 However, much of the variation in QT remains 
unexplained.
To date, the majority of published GWAS of QT have been conducted in populations of 
European descent.8-10 Few studies have examined the relevance of GWAS-identified QT 
SNPs in multi-ethnic populations,12,13 although such studies are needed to fully understand 
the genetic architecture underlying QT. Therefore, we examined evidence of generalizability 
for 21 SNPs associated with QT in previous GWAS8-10 across populations of African, 
American Indian, Hispanic, and Asian descent from the Population Architecture using 
Genomics and Epidemiology (PAGE) Study.
Methods
Study Populations
The PAGE study is a collaboration of four large, multiethnic, and deeply phenotyped 
consortia.14 Using the ethnically diverse populations of the participating studies, the goal of 
PAGE is to better understand the epidemiologic architecture of well-replicated genetic 
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variants associated with complex disease in global populations. Three PAGE consortia 
contributed the following studies to this research: the National Health and Nutrition 
Examination Surveys (NHANES) through the Epidemiologic Architecture for Genes Linked 
to Environment study,15 the Women's Health Initiative Clinical Trial through the Women's 
Health Initiative (WHI),16 and the Causal Variants Across the Life Course Consortium 
which included the Atherosclerosis Risk in Communities study,17 the Cardiovascular Health 
Study,18 the Strong Heart Study,19 and the Strong Heart Family Study.20 Each study was 
approved by the Institutional Review Board at the respective sites and all participants 
provided written consent. Further details on each study are available in eAppendix.
A total of 42,525 participants from the above studies were genotyped in PAGE. Of these, 
10,051 were excluded according to the following hierarchical criteria (eTable 1): QT 
information unavailable (n=5,286); poor ECG quality (grade=5, n=1,654); major conduction 
defects, including left- or right-bundle branch block and intraventricular conduction delay 
(n=1,197); QRS interval ≥ 120ms (n=662); pacemaker or defibrillator implants (n=20); atrial 
fibrillation or atrial flutter on baseline ECG (n=44); participants under 18 years of age 
(n=334); and genetic ancestry data unavailable (n=854).
QT-Interval Measurement
In each study, certified technicians recorded at baseline, resting, supine (or semi-recumbent), 
standard 12-lead ECGs using either Marquette MAC 12 or MAC PC machines (GE 
Healthcare, Milwaukee, WI, USA). Comparable procedures were used for preparing 
participants, placing electrodes, recording, transmitting, processing, and controlling quality 
of ECGs. The QT-interval was measured electronically using Marquette 12SL algorithm. 
ECGs from Atherosclerosis Risk in Communities study, Cardiovascular Health Study, and 
Women's Health Initiative were processed by the central Epidemiological Cardiology 
Research Center at Wake Forest University, Winston-Salem, NC, USA. Epidemiologic 
Architecture for Genes Linked to Environment study, Strong Heart Study and Strong Heart 
Family Study ECGs were read at independent ECG reading centers using comparable 
protocols (eTable 2).
SNP Selection and Genotyping
The 21 SNPs examined in this study were reported by previously published QT GWAS (as 
of January 2010). The SNPs represent 12 genetic loci, with multiple SNPs reported for 
NOS1AP (4 SNPs), KCNH2 (3 SNPs), KCNQ1 (3 SNPs), PLN (2 SNPs) and SCN5A (2 
SNPs). The 21 SNPs examined here were either targeted for genotyping by the PAGE study 
or were available on previous GWAS chips. Genotyping was done separately by each study 
(eAppendix). Cross-study quality control was performed centrally by the PAGE 
Coordinating Center using 360 samples from the International HapMap Project that were 
genotyped by each participating study.
Statistical Analysis
Study- and race-stratified tests of association between each SNP and QT (in milliseconds 
[ms]) were performed using linear regression models, and assuming an additive genetic 
mode of inheritance. We included the following confounders: study site (where appropriate), 
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sex, age (continuous in years), RR interval (ms) or heart rate (beats per minute) when RR 
interval was not measured directly, and ancestral principal components that assessed global 
ancestry among study participants. Results were combined by inverse-variance weighted 
meta-analysis using METAL,21 and heterogeneity was evaluated using Cochran's Q 
statistic.22 P-values were 2-sided.
Generalizability of SNPs originally identified in European descent populations was assessed 
by examining the direction, precision, and magnitude of estimated effects across racial/
ethnic groups. SNPs were considered directionally consistent if their direction of effect was 
the same across populations. For each non-European descent population, we categorized 
SNPs as stronger than, weaker than, or equal (within 0.05 ms) to the estimates from the 
European-descent population, based on the absolute value of the estimated effect sizes. 
Precision was gauged using the 95% confidence limit difference (CLD).
Haplotype Block Analysis
Given the potential for variation in linkage disequilibrium (linkage disequilibrium) patterns 
between SNPs across racial/ethnic groups,23 haplotype blocks were examined using 
HapMap III data.24 Briefly, we calculated pairwise measures of linkage disequilibrium using 
Hedrick's multiallelic D′, and we generated linkage disequilibrium plots using Haploview 
4.225 and dense genotype data from five International HapMap III populations: African 
Americans from the southwest U.S., Utah residents of northern and western European 
ancestry, Han Chinese from Beijing, China, Japanese from Tokyo, Japan, and a Mexican 
American population from Los Angeles, CA. In accordance with convention, data from the 
Chinese and Japanese populations were pooled before analysis and referred to as “Asian.”
Results
Study Population Characteristics
A total of 32,474 participants from the PAGE consortium were included in this analysis with 
the following breakdown by race/ethnicity: European American (n=18,802), African 
American (n=6,132), American Indian (n=5,465), Hispanic (n=1,143), and Asian (n=932) 
(Table 1). All studies contributed approximately equal proportions of male and female 
participants, with the exception of the Women's Health Initiative Clinical Trial, which 
enrolled only female participants. Notably, the Women's Health Initiative Clinical Trial was 
the only study contributing participants of Asian descent. Estimated mean age varied slightly 
by race/ethnicity, with the highest mean age observed among European Americans (63.8 
years) and the lowest among American Indians (59.1 years). Mean QT was consistent across 
race/ethnicity (range = 403 ms – 405 ms).
Evidence of variation in allele frequency by race/ethnicity was observed for a majority of 
GWAS-identified QT SNPs (Table 2). For example, we observed mean allele frequency 
differences between populations greater than 20% for thirteen SNPs. The two most striking 
differences were for rs12053903 and rs4725982, both of which had a difference of 44% 
between the lowest and highest frequency; for rs12053903, this difference translated to a 
coded allele frequency of 33% in European Americans and 77% in African American, while 
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for rs4725982, the largest difference was between European Americans (22%) and Asians 
(66%).
Summary Results Among European-Descent Populations
After meta-analysis, 20 of 21 SNPs (95%) representing all 12 genetic loci were associated 
with QT in European Americans, with little evidence of study heterogeneity (eTables 3 and 
4). The only European ancestry-identified SNP that was not associated with QT was 
rs12053903 (intronic to SCN5A), which had an estimated effect size of -0.21 (95% 
confidence interval [CI] = -0.86 to 0.45). For the remaining 20 SNPs, the estimated direction 
and magnitude of effects were consistent with previously published results.
Generalizability of GWAS-Identified QT SNPs to Populations of Non-European Descent
Direction and Precision of Effect—Seven of the 21 previously reported QT SNPs 
(33%) had a consistent direction of effect across all populations (Figure 1). These seven 
SNPs (rs12143842, rs12029454, rs11129795, rs2074238, rs37062, rs2074518, and 
rs1805128) represented six genetic loci (NOS1AP, SCN5A, KCNQ1, NDRG4, LIG3 and 
KCNE1). Results were noticeably less precise for rs2074238 and rs1805128 (imprecise in all 
four non-European populations) than for the other five SNPs, which were precise in all five 
populations. Estimated imprecision for these two SNPs likely reflects the low estimated 
minor allele frequency across race/ethnicity (0.02 – 0.08 frequency for rs2074238; 0.002 – 
0.01 for rs1805128) and a smaller sample size for rs2074238. Additionally, rs12143842, 
rs37062, and rs1805128 showed heterogeneity within at least one race/ethnicity (eTables 
5-7).
Nine SNPs (43%) showed a consistent direction of effect in four of the five populations 
(Figure 1). These nine SNPs (rs17779747, rs12053903, rs11756438, rs4725982, rs2968864, 
rs2968863, rs10919071, rs10494366, and rs12296050) represented seven loci (KCNJ2, 
SCN5A, PLN, KCNH2, ATP1B1, NOS1AP, and KCNQ1). There was no race/ethnicity 
identified as an outlier across these nine SNPs: the directionally inconsistent effect estimate 
was observed in the African American, Asian, and American Indian populations four, three, 
and two times, respectively. Of these nine SNPs, imprecision was noted among Hispanic 
and Asian subpopulations for rs10919071 and rs2968863 and in Asians alone for rs2968864 
and rs17779747; these groups had smaller sample sizes than the other race/ethnic groups. 
Additionally, two SNPs (rs4725982 and rs12296050) in African Americans and five SNPs 
(rs2968864, rs2968863, rs4725982, rs12296050, and rs17779747) in American Indians 
showed within-population heterogeneity in American Indians (eTables 5-7).
The remaining five SNPs (24%: rs12210810, rs16857031, rs846111, rs12576239, and 
rs8049607) showed considerable variation in direction of effect across race/ethnicity, with 
notable variation in precision.
Magnitude of Effect—In general, populations of non-European descent were more likely 
to have weaker estimated effect sizes than the European American population, although we 
found some variation in precision, particularly for Hispanic and Asian populations (eTable 
3). Evidence of effect attenuation was particularly apparent among African American 
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participants (18 of 21 SNPs with effects closer to the null). Notably, Hispanics were equally 
likely to have weaker or stronger effects compared with European-descent populations.
Heterogeneity of Estimated Effects Across Race/Ethnicity
Overall, evidence of heterogeneity was observed for 12 of the 21 examined SNPs (57%). Of 
the seven directionally consistent SNPs, heterogeneity of P < 0.05 among racial/ethnic 
groups was observed for two NOS1AP SNPs (rs12143842 [P = 2×10-3] and rs12029454 [P = 
2×10-5]) (Figure 1, eTable 8). Among the nine SNPs showing a consistent direction of effect 
in four populations, seven demonstrated notable heterogeneity among groups: rs109109071, 
rs111756438, rs10494366, rs4725982, rs12296050, rs2968863, and rs2968864. For SNPs 
with an inconsistent direction of effect, heterogeneity of P < .05 was observed for three of 
these five SNPs (rs8049607 [P = 1×10-8], rs12576239 [P = 2×10-4], and rs846111 [P = 
0.04]).
Haplotype Structure
Given the substantial evidence of among-race heterogeneity, we examined linkage 
disequilibrium patterns using data from five HapMap 3 populations to determine whether 
the observed heterogeneity of effect could be attributed to differences in linkage 
disequilibrium among racial/ethnic groups. For example, a large haplotype block surrounded 
rs12143842 (test for heterogeneity among racial/ethnic groups, P = 0.002) in the European 
ancestry (24 kilobases [kb]), Asian ancestry (14 kb), and Hispanic ancestry (10 kb) 
populations (Figure 2). However, for African Americans, the haplotype block containing 
rs12143842 was much smaller (4kb) and did not contain any SNPs downstream of 
rs12143842. Another example of population-specific linkage disequilibrium patterns that 
may help explain the observed heterogeneity was provided by rs2968864 (test for 
heterogeneity, P = 0.03), which exhibited marked variation in effect size and haplotype 
block structure by race/ethnicity. Conversely, rs17779747, which did not exhibit among-race 
heterogeneity (P = 0.2), showed very similar linkage disequilibrium patterns across HapMap 
populations.
Discussion
In this study, we evaluated evidence of generalizability for 21 index QT SNPs identified by 
prior GWAS of European descent populations in multi-ethnic populations from the PAGE 
study. Evidence of heterogeneity of effect across race/ethnicity was observed for a majority 
of SNPs, including SNPs from NOS1AP, the most commonly identified QT locus.8-10,12,13 
Analyses of HapMap 3 populations suggested that variation in estimated effect by race/
ethnicity may reflect underlying variation in linkage disequilibrium among race/ethnicity. 
Variation in linkage disequilibrium patterns as a cause for estimated effect size variation is 
further supported by the weaker effects seen in African Americans, where linkage 
disequilibrium blocks are smaller, which suggests that the causal SNPs may not be as 
effectively tagged as in European Americans.
Heterogeneity of effect by race/ethnicity can reflect several phenomena, including variation 
in linkage disequilibrium among populations,23 allelic heterogeneity (i.e. the same locus but 
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different causal variants influencing a trait across populations),26 or gene-gene and gene-
environment interaction.27 Variation in linkage disequilibrium by race is a plausible source 
of the observed heterogeneity, given that several PAGE populations, particularly African 
Americans and Hispanics, have smaller linkage disequilibrium blocks than populations of 
European descent.23 For this reason, the index SNPs identified in European American 
populations may not tag the underlying causal SNP in populations of African or Hispanic 
descent because it resides in a different linkage disequilibrium block.
Another potential cause of heterogeneity of effect across race/ethnicity is allelic 
heterogeneity, which has been demonstrated by studies of other ECG traits, particularly the 
PR interval.28 In addition to the potential for race/ethnicity-specific alleles influencing QT, 
allelic heterogeneity is complicated by the potential for rare causal variants that can create 
“synthetic” signals. GWAS-identified index SNPs, including QT index SNPs, could simply 
represent a collection of rare causal variants, which would likely differ among populations – 
rather than a single causal SNP.29 As the number of rare variants increases, so too does the 
potential for these synthetic associations to be found.29 Thus, estimated effects would be 
expected to differ among racial/ethnic groups, as the SNPs evaluated above are 
representative of a diverse collection of rare variants.
Furthermore, heterogeneity of effect could be caused by underlying gene-gene or gene-
environment interaction, especially if potential modifiers vary among populations. Previous 
studies have shown interaction between genetic variants and QT-altering pharmaceuticals, 
although only a single SNP examined in this study (rs1805128) was previously identified as 
a potential modifier in a large pharmacogenomics effort examining QT.30 Additionally, 
lifestyle factors (including physical activity, rest/sleep, and emotional stimuli) may also 
interact with genetic variants associated with long-QT syndromes,31 although few studies 
have evaluated these potential modifiers in large population-based samples. Gene-gene 
interactions also are biologically plausible causes of heterogeneity, given evidence of 
population-specific variants influencing QT.32 However, very few studies have examined 
the influence of gene-gene interactions with QT, given the immensity of the task of testing 
interactions among millions of GWAS variants.
Regardless of the source of heterogeneity, these results, as well as studies of other heritable 
traits including type 2 diabetes33 and obesity,34 suggest that genomic studies of ancestrally 
diverse populations should analyze racial/ethnic groups separately, unless strong evidence of 
homogeneity is observed. However, the pooling of results across these groups is common in 
genetic epidemiology studies, particularly when there are small samples of non-European 
populations.35,36 A similar practice is the meta-analysis of summary results across racial/
ethnic background,37,38 although for common variants this approach is equivalent to 
pooling.39 Therefore, strategies that pool or meta-analyze results across race implicitly 
assume that the index SNP tags the causal variant across all populations; they also assume 
the absence of allelic heterogeneity and among-race gene-gene or gene-environment 
interactions. Instead, to fully understand the genetic architecture underlying disease in 
diverse populations, studies should allow for these potential differences across distantly 
related populations and analyze them independently.
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Although a hurdle for researchers who wish to combine results, genetic heterogeneity can be 
leveraged to identify novel genes and narrow intervals flanking index SNPs.23 For example, 
fine-mapping studies are particularly relevant among admixed populations such as African 
Americans, Hispanics/Latinos, and American Indians. For QT, fine mapping has been 
conducted in African Americans32 to refine the region of association surrounding several 
genes and identify novel NOS1AP and ATP1B1 SNPs specific to African Americans. The 
evidence of heterogeneity identified by our study further underscores the potential utility of 
fine-mapping studies in other populations, which could harness among-population 
differences in linkage disequilibrium to refine regions of association and identify additional 
SNPs influencing QT.
This study had several notable limitations. First, sample sizes in non-European American 
populations were modest, especially for Asian Americans, and thus produced less precise 
estimates. Nonetheless, few studies to date have examined associations between genetic 
variants and QT across five distinct racial/ethnic groups. Second, SNPs were selected in 
2010 and therefore did not reflect more recent publications.12 However, since SNP 
selection, only one new genetic locus (SLC8A1) has been identified for QT,12 ensuring that 
our results remain contemporary. Additionally, we did not account for potential 
comorbidities in our primary analysis, as was done in previous GWAS. However, our results 
were robust to the exclusion of participants with prevalent stroke and prevalent ischemic 
heart disease (eTable 9). Furthermore, variations in ECG machines, sampling rates (250 Hz 
vs. 500 Hz), and reading software between studies (eTable2) could have accounted for a 
portion of the heterogeneity observed among studies. A sensitivity analysis comparing 
results using two reading algorithms and sampling rates (Dalhousie at 250 Hz, Marquette 
12-SL at 500 Hz) among Women's Health Initiative participants showed little change in the 
effect estimates between the two methods and no change in the overall conclusions, 
indicating that differences in ECG methods likely had little effect on the results (eTable 10). 
Finally, we estimated effects of small magnitude that likely explained only a small fraction 
of the variation in QT. However, these results have potential clinical and regulatory 
relevance. The Food and Drug Administration's standard for regulating QT-prolonging 
pharmaceuticals is a change of QT interval of 5ms,40 a threshold that is easily met when 
considering combinations of SNPs. Furthermore, our results suggest that the 21 SNPs are 
likely tag SNPs, which are expected to have smaller effects when compared to the 
underlying causal SNP.
In conclusion, our findings suggest the presence of considerable heterogeneity among racial/
ethnic groups for previously identified QT index SNPs that may reflect several phenomena, 
including population-specific linkage disequilibrium patterns. More broadly, our results 
underscore the utility of examining heterogeneity by race/ethnicity in genetic association 
studies. Further characterization of these loci across multi-ethnic populations, including 
large-scale genotyping, is needed to provide additional insights into the genetic architecture 
of QT.
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Refer to Web version on PubMed Central for supplementary material.
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Forest Plots of Risk Variants Effect Sizes (95% Confidence Interval) for a Race/Ethnicity-
Stratified Meta-Analysis of 32,474 Participants From Six Participating PAGE Studies.
Abbreviations: A, Asian; AA, African American; AI, American Indian; EA, European 
American; H, Hispanic; Phet, Two sided P-value for test of heterogeneity across populations;
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Linkage disequilibrium Plots (D′) from Haploview for Selected Risk Variants Across Four 
Global Populations.
All populations come from International HapMap III populations. Abbreviations: ASW, 
Samples of African American Ancestry; CEU, Samples of European Ancestry; CHB-JPT, 
Samples of Asian Ancestry; MEX, Samples of Hispanic Ancestry.
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Total 18,802 65 64 (3) 405 (15)
ARIC 10,926 53 54 (6) 399 (29)
CHS 2,508 64 72 (5) 413 (32)
EAGLE 1,291 60 63 (14) 409 (33)
WHI CT 4,077 100 63 (7) 402 (29)
African Americans
Total 6,132 69 62 (3) 403 (17)
ARIC 4,020 63 54 (6) 400 (33)
CHS 492 67 72 (6) 405 (34)
EAGLE 578 56 55 (12) 406 (33)
WHI CT 1,042 100 60 (7) 401 (34)
American Indians
Total 5,465 65 59 (5) 404 (18)
SHS 2,200 64 63 (8) 408 (33)
SHFS 3,086 64 42 (16) 408 (33)
WHI CT 179 100 59 (6) 398 (29)
Hispanics
Total 1,143 71 60 (6) 405 (21)
EAGLE 655 50 56 (12) 405 (30)
WHI CT 488 100 61 (7) 404 (30)
Asians
WHI CT 932 100 62 (7) 405 (33)
a
Overall mean calculated using inverse-variance weighted method
ARIC indicates Atherosclerosis Risk in Communities; CHS, Cardiovascular Health Study; EAGLE, Epidemiologic Architecture for Genes Linked 
to Environment study; WHI CT, Women's Health Initiative Clinical Trial; SHS, Strong Heart Study; SHFS, Strong Heart Family Study
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